Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q4 FY26 results · Jan–Mar 2026
Tatva Chintan Pharma Chem reported revenue from operations of ₹134.14 crore (up 24.4% from Q4 FY25) and net profit of ₹10.32 crore (up 902.0% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 134.14 | 107.86 | +24.4% | 131.33 | +2.1% |
| Other income | (0.35) | 0.72 | Turned loss | 1.73 | Turned loss |
| Total income | 133.80 | 108.59 | +23.2% | 133.07 | +0.5% |
| Profit before tax | 16.59 | 2.03 | +718.3% | 17.66 | −6.1% |
| Net profit for the period | 10.32 | 1.03 | +902.0% | 15.16 | −31.9% |
| EPS, basic (₹) | 4.41 | 0.44 | +902.3% | 6.49 | −32.0% |
| Net margin (%) | 7.7 | 1.0 | 11.5 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 132.66 | 107.65 | +23.2% | 138.59 | −4.3% |
| Other income | (0.37) | 1.29 | Turned loss | 1.73 | Turned loss |
| Total income | 132.30 | 108.94 | +21.4% | 140.32 | −5.7% |
| Profit before tax | 14.97 | 1.55 | +863.6% | 18.79 | −20.3% |
| Net profit for the period | 9.02 | 1.09 | +724.0% | 15.98 | −43.5% |
| EPS, basic (₹) | 3.86 | 0.47 | +721.3% | 6.84 | −43.6% |
| Net margin (%) | 6.8 | 1.0 | 11.5 |
Consolidated
- Filed with BSE
- 16 May 2026, 20:51 IST
- Board meeting
- 16 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 May 2026, 20:51 IST
- Board meeting
- 16 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE